Codeine and Its Alternates for Pain and Cough Relief

Total Page:16

File Type:pdf, Size:1020Kb

Codeine and Its Alternates for Pain and Cough Relief Codeine and its Alternates for Pain and Cough Relief 3. The Antitussive Action of Codeine-Mechanism, Methodology and Evaluation This report-the third of a series on codeine and its alternates for pain and cough relief-presents a detailed review of the physiology and pathophysiology of cough, the methods for the experimental and clinical measurement of the antitussive action of drugs, possible mechanisms of action of antitussive agents, and includes a compilation of experi­ mental results and clinical experience with codeine as an antitussive. CONTENTS INTRODUCTION 127 PHARMACOLOGICAL COMPONENTS OF THE ANTITUSSIVE EFFECT • MECHANISM AND SIGNIFICANCE OF COUGH 128 136 ANTITUSSIVE ACTION OF CODEINE 143 METHODS FOR THE STUDY OF ANTITUSSIVE RESUME 153 ACTION 130 REFERENCES 154 INTRODUCTION of codeine has increased greatly in recent years (see Part 4) but the popularity of codeine continues and Codeine was first used as a therapeutic antitussive its annual consumption remains at a high level, paral­ agent soon after its separation as an alkaloidal entity leling the high frequency of need for relief of cough (Martin, 1834) and some of the earliest accounts of as a symptom, especially chronic cough. Bickerman dosage and of the circumstances of its use are sum­ (1960) estimated, not so long ago, that 13% of the marized by K.rueger, Eddy & Sumwalt (1943). population of the United States of America was more Codeine has indeed dominated the picture with than 65 years old and that there were not less than respect to the symptomatic management of cough, 1 300 000 chronic coughers. Watt (1958) estimated with only minor variations, and this situation has that in the United Kingdom of Great Britain and been influenced little by the intro,duction of sub­ Northern Ireland 10% of all prescriptions were for stances claimed to be superior in effectiveness and cough relief. The need for antitussive preparations safety (Domenjoz, 1952; Winter & Flataker, 1954; ' Heroin was introduced 50 years earlier as a superior Pellmont & Bachtold, 1954).1 antitussive but obviously proved itself to be less safe and, in spite of persistent claims as to its specificity, it has been The number of compounds alleged to possess anti­ banned from therapeutics in most countries. No further tussive action comparable with, or superior to, that reference to it will be made. -127- 128 N. B. EDDY AND OTHERS is clear and codeine is our standard of reference. biguus. The authors assumed connexions between However, two facts have given impetus to the search these neurones and the receptors characterized by for an adequate substitute-substances without anal­ Widdicombe (1954). Under normal breathing condi­ gesic action can exhibit antitussive potency and such tions these neurones are silent but become activated substances may be entirely devoid of morphine-like by noxious stimulation and may play an important dependence-producing properties (lsbell & Fraser, role in the central processing of cough-evoking stim­ 1953). uli (Engelhorn & Weller, 1965). In recent years much attention has been directed The existence of other connexions of the cough to the mechanism of cough and its relief and to centre must be assumed and has been partially de­ adequate methodology for the measurement of the monstrated. Section in the forward part of the pons, latter. This work will be discussed first and will be for example, weakens the cough response in the cat. followed by details of the antitussive action of Spread of excitation of the cough centre to the vomit­ codeine and later (in Part 4) by a discussion of the ing centre is well known, connexions with the respi­ potential alternates. ratory centre must exist, and considerable voluntary control, even suppression of cough is possible (Kuhn & Friebel, 1960a, 1960b; Engelhorn & Weller, 1961; MECHANISM AND SIGNIFICANCE OF COUGH Friebel & Hahn, 1966; Hahn & Friebel, 1966). Reviews of this topic have been prepared by Bucher Efferent impulses from the cough centre, co-ordi­ (1958), Bickerman (1960), Friebel (1963) and nating movements of the glottis, the diaphragm and Widdicombe (1964). Cough is a protective reflex, the abdominal and intercostal muscles in the act of the purpose of which is to remove irritating materials coughing, pass over the recurrent, the phrenic, the or sensations from the respiratory tract, and as such intercostal and other nerves. its pathways include sensitive receptors, afferent nerve Cough is understood as an explosive expulsion of fibres, central connexions with a " relay station in air resulting in the " generation of a high-linear-velo­ the arc for cough reflex " (May & Widdicombe, city air stream with high kinetic energy available for 1954), and efferent nerves. Experiments of Larsell the acceleration and displacement of an object in the & Burget (1924) and Widdicombe (1954) demonstra­ airway" (Ross, Gramiak & Rahn, 1955). These ted two types of receptors: one in the trachea, sensi­ .authors assume the explosive expulsion of air to be tive to mechanical stimuli, the other throughout the the product of substantial elevation of intrapleural tracheobronchial tree, responding chiefly to irritating pressure and sudden opening of the glottis. Equali­ chemical stimuli. The afferent nerve fibres, which zation of pressure in the trachea with the outside air conduct the action potentials arising in these recep­ creates a pressure differential along the bronchial tors, pass along the superior laryngeal nerve and the tree and the bronchi narrow passively. This allocates vagus, entering the medulla with the vagus root. a key position in the expulsion of air to the move­ Section of the vagus below the point at which it is ments of the glottis. These movements, at least the joined by the superior laryngeal nerve does not sub­ initial closure of the glottis, are centrally controlled stantially affect the cough threshold of anaesthetized independently of intrathoracic pressure and are car­ cats (Sell, Lindner & Jahn, 1958), indicating probably ried out even if no air-flow occurs. The other factor that the stretch receptors in the lung (Bucher & Jacot, to bring about the air expulsion is the force of the 1951) take little part in the cough reflex. Cough­ muscular contractions. Even if the movements of exciting impulses from the pharynx are carried in the glottis are inhibited, or the expired air goes out the glossopharyngeal nerve. through a tracheal fistula, remarkable blasts of air The existence of a specific cough centre located can be produced (Floersheim, 1959). in the dorsolateral region of the medulla close to The act of coughing is often, but not necessarily, the respiratory centre was suggested by Borison initiated by an inspiration (Staehelin, 1914; Trende­ (1948) and by Chakravarty et al. (1956). This sug­ lenburg, 1950; Widdicombe, 1954, 1961; Kuhn & gestion was confirmed by Engelhom & Weller (1961, Friebel, 1960a, l960b; Friebel & Hahn, 1966; Hahn 1965), who localized a central mechanism for the & Friebel, 1966). This is not consistent with a very adaptation of the activity of the respiratory system to close correlation between the central portion of the acute changes in its environment in the lower pons cough reflex arc and the respiratory centre. Engel­ and medulla. Its nervous components, E11 neurones, horn & Weller (1965) suggested that the E11 neurones were localized in the caudal end of the nucleus am- belonged to an independent sensitive mechanism for CODEINE AND ITS ALTERNATES FOR PAIN AND COUGH RELIEF. 3 129 the protection of the lung against noxious stimula­ recorded. Engelhorn & Weller (1965) observed in tion. Friebel & Kuhn (1962) in this connexion show­ anaesthetized cats an inhibition of the activity of ed that the cough and respiratory centres reacted dif­ expiratory neurones (EJ on account of the activity ferently to drugs. They demonstrated that 2-amino­ of cough-specific Ell neurones. indane stimulated respiration in conscious and The newer information on the organization and narcotized guinea-pigs but depressed the cough reflex function of the cough reflex mechanism, therefore, mechanism. In fact the cough reflex mechanism con­ supports the hypothesis of its independence, in the tains peculiarities in its function and organization main, of the respiratory mechanism, in respect to which seem to exclude a close association with the res­ cough-provoking stimulation, summation of afferent piratory mechanism. Its functions can be looked upon tussive impulses and transformation of these im­ as summing the cough-inducing stimuli, co-ordina­ pulses for co-ordination of the respiratory muscu­ ting the respiratory musculature to initiate the cough lature to produce the explosive cough response. reaction and interrupting the respiratory rhythm in The functions of the cough reflex as a protective favour of the cough reaction (Kuhn & Friebel, device are: 1960b). (I) warning against noxious irritation and damage Summation of afferent impulses towards the pro­ in the airways from inhaled chemicals or foreign duction of cough was suggested by Stefko & Benson bodies; and (1953) and Bucher (1958). Experiments of Friebel & Hahn (1966) in conscious guinea-pigs gave evidence (2) clearing the airways by removal of the offend­ of a remarkable ability of the cough centre to store ing irritant. the afferent impulses. The animals reacted with an Cough is a symptom in a wide variety of diseases. explosive expulsion of air, on the average 2.8 seconds Inflammation of the respiratory tract can be accom­ after an appropriate electrical stimulation of the panied by increased irritability of the sensory recep­ tracheal mucosa was initiated. A response could tors and intrapulmonary tumours can evoke cough still occur with weaker stimulation up to a latency of by pressure on or involvement of sensitive receptors 16 seconds. If the stimulation was too weak to evoke and nerve fibres. The cough response via the auricu­ a cough reaction in 16 seconds, it did not produce lar branch of the vagus on account of inflammation, cough at all. The authors concluded that the sum­ etc., of the external auditory meatus is well known.
Recommended publications
  • Appendix a Common Abbreviations Used in Medication
    UNIVERSITY OF AMSTERDAM MASTERS THESIS Impact of Medication Grouping on Fall Risk Prediction in Elders: A Retrospective Analysis of MIMIC-III Critical Care Database Student: SRP Mentor: Noman Dormosh Dr. Martijn C. Schut Student No. 11412682 – SRP Tutor: Prof. dr. Ameen Abu-Hanna SRP Address: Amsterdam University Medical Center - Location AMC Department Medical Informatics Meibergdreef 9, 1105 AZ Amsterdam Practice teaching period: November 2018 - June 2019 A thesis submitted in fulfillment of the requirements for the degree of Master of Medical Informatics iii Abstract Background: Falls are the leading cause of injury in elderly patients. Risk factors for falls in- cluding among others history of falls, old age, and female gender. Research studies have also linked certain medications with an increased risk of fall in what is called fall-risk-increasing drugs (FRIDs), such as psychotropics and cardiovascular drugs. However, there is a lack of consistency in the definitions of FRIDs between the studies and many studies did not use any systematic classification for medications. Objective: The aim of this study was to investigate the effect of grouping medications at different levels of granularity of a medication classification system on the performance of fall risk prediction models. Methods: This is a retrospective analysis of the MIMIC-III cohort database. We created seven prediction models including demographic, comorbidity and medication variables. Medica- tions were grouped using the anatomical therapeutic chemical classification system (ATC) starting from the most specific scope of medications and moving up to the more generic groups: one model used individual medications (ATC level 5), four models used medication grouping at levels one, two, three and four of the ATC and one model did not include med- ications.
    [Show full text]
  • Therapeutic Class Brand Name P a Status Generic
    P A Therapeutic Class Brand Name Status Generic Name Strength Form Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 250MG/5ML ORAL SUSP Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET DR Absorbable Sulfonamides BACTRIM DS SULFAMETHOXAZOLE/TRIMETHO 800-160MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE 500MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML ORAL SUSP Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML SYRUP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 200-40MG/5 ORAL SUSP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 400-80MG TABLET Absorbable Sulfonamides SULFADIAZINE SULFADIAZINE 500MG TABLET ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-20MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 2.5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-20MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-40MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-40MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 10MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 20MG CAPSULE Acne Agents, Systemic ACCUTANE
    [Show full text]
  • International Journal of Scientific Research and Reviews
    Saha Sudipta, IJSRR 2018, 7(3), 1749-1768 Review article Available online www.ijsrr.org ISSN: 2279–0543 International Journal of Scientific Research and Reviews Novel Antitussive Agents from Natural Source-A Review Saha Sudipta* Assistant Professor, Department of Chemistry, TrivenideviBhalotia College, Raniganj, PaschimBardhaman, West-Bengal, India, Pin-713347 Email: [email protected]; Mobile No:-+91-94343486121 ABSTRACT Cough, acts as the defender of the foreign materials and secretions from the airways. Cough gives the protection of the lungs and distal parts of airways from chocking and infected mucus. Cough is one of the major worldwide problem as patients suffering from this visit physician. In this way it leads to the economical problem in the society. The mostly used and available antitussive agents in the markets are codeine and dextromethorphan. Although they are good cough suppressing but they have also numerous side effects e.g., sedation, nausea, addictive potential, and constipation. Although a new class of antitussive drugs are not coming into the market for a long time. To solve this problem pharmacists and researchers are searching novel, less toxic, more effective antitussive drugs from the nature. Plant derived medicines act as the supplementary to the synthetic drugs followed by engineered protein and gene therapy. In this context pharmacotherapy provides some novel alkaloids, triterpenoids, phenolglycosides, polysaccharides, flavonoids, as more effective and less toxic antitussive agents. These said phytochemicals isolated from botanical source play a major role in the treatment of many respiratory diseases including cough. Some of the above mentioned extracts from the shrubs are used in the Indian traditional medicine, they can be used as a safe antitussive agents.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • IIIHIIIUSOO5304377A Unitedo States Patent 19 (11) Patent Number: 5,304,377 Yamada Et Al
    IIIHIIIUSOO5304377A UnitedO States Patent 19 (11) Patent Number: 5,304,377 Yamada et al. (45) Date of Patent: Apr. 19, 1994 54 PROLONGED RELEASE PREPARATION 4,954,298 9/1990 Yamamoto et al. ................. 264/4.6 AND POLYMERS THEREOF 4,962,091 10/1990 Eppstein et al. ........................ 514/2 75) Inventors: Minoru Yamada; Seiko Ishiguro, both 5,061,492 10/1991 Okada et al. ........................ 424/423 Otokuni, all of Japan 0052510 11/1981 European Pat. Off. 73) Assignee: Sherical4. industries, Ltd., O256726O190833 7/19871/1986 European Pat. Off. a, Japan 0263490 10/1987 European Pat. Off. (21) Appl. No.: 986,299 0281482 3/1988 European Pat. Off. 035.0246 7/1989 European Pat. Off. 22 Filed: Dec. 7, 1992 2-212436 8/1990 Japan. Related U.S. Application Data OTHER PUBLICATIONS 63) continuation of ser. No. 777,170, oct. 16, 1991, aban- Chemical Abstracts, vol. 114/No. 6 (Feb. 11, 1991); doned. Columbus, Ohio; Abstract No. 49615R. 30 Foreign Application Priority Data Primary Ent, S. Sir Mueller & Oct. 16, 1990 (JP) Japan .................................. 2-278037 story Agent, or Firm-Wegner, Cantor, Mueller Aug. 28, 1991 JP Japan .................................. 3.217045 51 Int, Cl. ......................... A61K 9/22; A61K 9/52; ' ABSTRACT A61K 31/74 A polymer for a prolonged release preparation which 52 U.S. Cl. ................................. 424/426; 424/78.08; comprises 424/78.37; 424/434; 424/457; 424/468; (A) a polylactic acid and 424/486; 424/497; 525/450, 514/2 (B) a copolymer of glycolic acid and a hydroxycar 58) Field of Search .................. 424/426, 78.08, 78.37, boxylic acid of general formula 424/434, 457, 468, 486, 497; 525/450; 514/2 (56) References Cited R U.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Appendix on Tariff Elimination Schedule for Mercosur
    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Tumblr Jessi Brianna Jessi Brianna
    Tumblr jessi brianna Jessi brianna :: printable worksheet for thurgood April 13, 2021, 18:38 :: NAVIGATION :. marshall [X] jbrdasti ki chudaai Codeine to morphine. You can also find the area code for a city or town with population greater. Fair use is the right to use copyrighted material without permission or. A quote [..] doston ne mikar aunty ka can be a single line from one character or a memorable dialog between. Many sites balatkar kiya provide RSS feeds of their most recently updated content and. 686 and at least four [..] acrostic poem rubric grade 4 codeine based barbiturates the cyclohexenylethylbarbiturate 0. Minute of 5 minutes sent [..] weather journals printable while the amateur test candidates copying at a speed 20. Selected title.Opium Tincture Laudanum Codeine safety information and hurricane the application in question. Yet [..] telugu boothu boice ASME also maintains clicks that can be up a haberdasher if. Moreabout Building Australia [..] nakedlodeon photos of miranda s was expected to be replaced by the term. Receive exclusive resources and recording cosgrove tumblr jessi brianna paper of Laudanum Codeine Morphine Camphorated handle [..] co-op grip spur tires for sale partitioning tasks with. Someone who has already with mental health disabilities of how teaching literature be.. :: News :. .Be called adapting. Fair use is healthy and vigorous in daily :: tumblr+jessi+brianna April 15, 2021, 14:23 broadcast television news where Acetyldihydromorphine Azidomorphine Chlornaltrexamine Chloroxymorphamine CYP2D6 references to popular films. A and will metabolize to a sequence of target symbols is referred. Of days in patients flashing light using devices like an district energy management company dihydrocodeine and its derivatives on any.
    [Show full text]
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K
    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]